Zacks Research Issues Positive Forecast for EW Earnings

Edwards Lifesciences Co. (NYSE:EW) – Equities research analysts at Zacks Research raised their Q3 2025 earnings estimates for shares of Edwards Lifesciences in a note issued to investors on Wednesday, December 11th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $0.61 per share for the quarter, up from their previous forecast of $0.60. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Edwards Lifesciences’ Q4 2025 earnings at $0.63 EPS, Q2 2026 earnings at $0.66 EPS, Q3 2026 earnings at $0.70 EPS and FY2026 earnings at $2.75 EPS.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same period last year, the firm earned $0.59 earnings per share.

A number of other analysts have also recently commented on the company. Citigroup upped their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday. Robert W. Baird cut their target price on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Evercore ISI decreased their price target on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. Jefferies Financial Group cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and lowered their price objective for the company from $85.00 to $70.00 in a research report on Wednesday, September 18th. Finally, JPMorgan Chase & Co. lifted their target price on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Seventeen investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $78.65.

Edwards Lifesciences Stock Down 0.9 %

Shares of Edwards Lifesciences stock opened at $73.32 on Friday. The business has a fifty day simple moving average of $69.42 and a 200 day simple moving average of $73.99. The stock has a market cap of $43.24 billion, a PE ratio of 10.58, a price-to-earnings-growth ratio of 3.63 and a beta of 1.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 12 month low of $58.93 and a 12 month high of $96.12.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of EW. FSA Wealth Management LLC acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at about $30,000. Prospera Private Wealth LLC acquired a new stake in shares of Edwards Lifesciences in the third quarter valued at approximately $32,000. Avior Wealth Management LLC lifted its position in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after buying an additional 308 shares during the last quarter. HHM Wealth Advisors LLC bought a new position in shares of Edwards Lifesciences during the 2nd quarter worth approximately $55,000. Finally, Peoples Bank KS acquired a new position in shares of Edwards Lifesciences during the 3rd quarter worth approximately $40,000. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling

In other news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. This represents a 11.18 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,077,593.52. This represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 35,000 shares of company stock worth $2,323,150. 1.29% of the stock is owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.